Rapamycin decreases proinflammatory and profibrogenic gene expression in experimental NASH
E Gäbele, K Dostert, C Dorn, G Koehl, EK Geissler, J Schoelmerich, C Hellerbrand · Zeitschrift für Gastroenterologie · 2009 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: Because of the increasing incidence of NASH and obesity in the western world, the use of fatty grafts for patients requiring liver transplantation is an evolving problem. Rapamycin, which has antifibrotic properties, is an immunosuppressant widely used after liver transplantation. Therefore, we hypothesized that rapamycin could attenuate profibrogenic and proinflammatory gene expression in a model of dietary NASH. Methods: Female Balb/c mice (n=4–6) were allocated into four experimental groups receiving standard chow (SC) or a high fat (HF) diet with or without rapamycin supplementation (5mg/kg bodyweight)…
